Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

This study tests a three-drug combination called OGL — orelabrutinib (a targeted therapy), obinutuzumab (an antibody), and lenalidomide (an immune-modulating drug) — as a first-line treatment for marginal zone lymphoma (MZL), a slow-growing type of non-Hodgkin lymphoma affecting lymph nodes, the spleen, or other organs. **You may be eligible if...** - You are 18 or older with confirmed marginal zone lymphoma (splenic, nodal, or extranodal type) - You have not received treatment before or need treatment due to symptoms or disease burden - You are in good to moderate health (ECOG 0–2) with expected survival over 3 months **You may NOT be eligible if...** - You have another active cancer - Your lymphoma involves the central nervous system - You have uncontrolled hepatitis B, HIV, or other severe active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.